Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Enhertu Gets Priority Review for HER2 Low or Ultralow Breast Cancer in US
Daiichi Sankyo said on October 1 that the US FDA has accepted for review Enhertu (trastuzumab deruxtecan), an antibody drug conjugate (ADC) being jointly developed with AstraZeneca, for certain patients with HER2 low or ultralow breast cancer. The FDA granted…
To read the full story
Related Article
- Enhertu Wins 5th China Indication in HER2-Low/Ultralow Breast Cancer
December 26, 2025
- Enhertu Approved for HER2-Low/Ultralow Breast Cancer in Europe
April 7, 2025
- Enhertu Gets EMA Backing for HER2-Low/Ultralow Breast Cancer
March 4, 2025
- Enhertu Approved for HER2-Low/Ultralow Breast Cancer
January 29, 2025
- Enhertu Filed for HER2 Low or Ultralow Breast Cancer in Japan
October 7, 2024
- Enhertu Bags Breakthrough Therapy Tag for HER2 Low or Ultralow Breast Cancer
August 20, 2024
BUSINESS
- Ex-Takeda CEO Weber Joins Rakuten Medical as Vice Chairman
September 10, 2026
- 3 Chugai Researchers Win Lasker Award for Hemlibra Discovery
September 10, 2026
- Elix, Axcelead DDP Forge Pact on Novel Protein Degraders
September 10, 2026
- CMIC Scraps Application Forms, Brings AI Avatars into New Grad Hiring
September 10, 2026
- Teijin, Shinshu University Link Arms on CAR-T Manufacturing
September 10, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…